News Daily News SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients The top-line results suggest a 14% lower risk of MACE compared with placebo for the once-daily pill added to standard care. L.A. McKeown October 23, 2024
Presentation TCT 2024 The Sound Science Behind Shockwave IVL's Mechanism of Action Presenter: Ziad Ali October 29, 2024
Presentation TCT 2024 Next Generation IVL Technology: Introducing Shockwave E8 Presenter: Peter Soukas October 29, 2024
Presentation TCT 2024 TCT 497: Sex-Specific Clinical Outcomes After Treatment of In-Stent Restenosis With the AGENT Paclitaxel-Coated Balloon: A Subgroup Analysis of the AGENT IDE Randomized Trial Presenter: Jennifer Tremmel October 29, 2024
Presentation TCT 2024 TCT 250: Temporal Trends in Ischemic Heart Disease-related Mortality in Canada Over the Past 3 Decades Presenter: Ahmed Abdulelah October 29, 2024
Presentation TCT 2024 Engineering the Future of tMCS: The Supira's Small Size Platform Presenter: Gagan Singh October 29, 2024
News Conference News TCT 2024 In STEMI, Giving Heparin Pre-Cath Lab May Boost Reperfusion: HELP-PCI By Yael L. Maxwell October 29, 2024
News Conference News TCT 2024 ECLIPSE: Orbital Atherectomy No Better Than Balloon Angioplasty in Calcified Lesions By Yael L. Maxwell October 29, 2024
News Conference News TCT 2024 DRAMI: No Clear Winner for Distal vs Traditional Radial Access in STEMI By Todd Neale October 29, 2024
News Conference News TCT 2024 DCB Outdo Noncompliant Balloons in Simple Bifurcation Side Branches: DCB-BIF By Caitlin E. Cox October 28, 2024
News Conference News TCT 2024 New DanGer Shock Data: Hemodynamics, Renal Dysfunction, and Bleeding By Caitlin E. Cox October 28, 2024